Clinical trial
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
NCT00001197 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00001197 |
|---|---|
| Title | Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia |
| Official title | Effect of Hydroxyurea on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Anemia |
| Intervention type | Drug |
| Interventions | Hydroxyurea |
| Enrollment | 41 |
| Start date | Feb 7, 1984 |
| Primary completion | Dec 21, 2003 |
| Completion | May 18, 2015 |
| First posted | Nov 4, 1999 |
| Last update posted | Dec 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: